IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Dayno et al.

JUN 2.1 2004 0 35

Serial No. 10/767025

Filed: January 29, 2004

For: COMBINATION THERAPY FOR THE TREATMENT OR

PREVENTION OF MIGRAINE

Art Unit: _	
Examiner:	

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, or the date appearing below.

MERCK & CO., INC

Date

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited
by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120
are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED AP	PLICATION	
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE	
If this is inconvenient, additional copies will be submitted upon re	quest.		
6. In accordance with 37 C.F.R. 1.97, (check one)			
the state of the s			

	or in absorbance man or on the nor, (onest one)
	the attached information is filed within three months of the filing date of the captioned case.
<u> </u>	the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
	the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p). the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
	the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Raga	?~
By: Raynard Yur	0
Attorney	For Applicant(s)

Reg. No. <u>45,570</u>
MERCK & CO., INC.
Patent Dept., RY60-30
P.O. Box 2000

Rahway, N.J. 07065-0907 (732)594-<u>0182</u>

Date: June 18, 2004

Substi	tute for form 1449A/PTO	COMPLETE IF KNOWN			
· INI	FORMATION DISCLOSURE	Application Number	10/767025		
S.T.	ATEMENT BY APPEIGANT	Filing Date	January 29, 2004		
517	ATEMENT BY AFFEIGANT	First Named Inventor	J. M. Dayno et al		
	JUN 2 1 2004 E)	Group Art Unit			
((use as man) sheets as necessary	Examiner Name			
Sheet	1 PADEMAN 2	Attorney Docket Number	21311		

U.S. Patent Document					Date of Publication of
Examiner Initials*	Cite No.	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
	Α	4,757,060		Lukackso et al.	07/12/1998
	В	5,037,815		Lukacsko et al.	08/06/1991
	С	5,071,842		Lukacsko et al.	12/10/1991
	D	6,248,363 B1		Patel et al.	06/19/2001
	E	US2001/0004644 A1		Levin	06/21/2001
	F	US2001/0055607 A1		Levin	12/27/2001
	G	US2002/0012680 A1		Patel et al.	01/31/2002
l.	Н	US2002/0034555 A1		Gelber et al.	03/21/2002
	I	US2002/0044962 A1		Cherukuri et al.	04/18/2002
	J	US2002/0082252 A1		Hochman	06/27/2002
	L	US2002/0103110 A1		Spitzer	08/01/2002
	M	US2002/0115081 A1		Lee et al.	08/22/2002

			FOREIG	N PATENT	T DOCUMENTS	
		Foreign Patent Document				Date of Publication of
Examiner Cite Initials* No.				Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
	Α	PCT	WO 98/03179			01/29/1998
	В	PCT	WO 99/20110		Merck & Co., Inc,	04/29/1999
	С	PCT	WO99/45905		Pozen Inc.	09/16/1999
	D	PCT	WO01/19336 A1		Cll Pharma	03/22/2001
	Е	PCT	WO01/28548 A1		Texas Heart Institute	04/26/2001
	F	PCT	WO01/30288 A1		Anesta Corporation	05/03/2001
	G	PCT	WO01/45683 A2		Glaxo Group Limited	06/28/2001
	Н	PCT	WO01/45683 A3		Glaxo Group Limited	06/28/2001
	I	PCT	WO02/05799 A2		Pharmacia Corporation	01/24/2002
	J	PCT	CA 1,303,995		Bristol-Myers Company	08/08/1986

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Substitute for form 1449A/PTO		<u>-</u>	COMPLETE IF KNOWN			
	INFORMATION	DIS	CLOSURE	Application Number	10/767025		
		' A TO	DI ICANT	Filing Date	January 29, 2004		
STATEMENT BY APPLICANT				First Named Inventor	Dayno et al.		
	•		,	Group Art Unit			
(use as many sheets as necessary)				Examiner Name			
Sheet	2	of	2	Attorney Docket Number	21311		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
				· · · · · · · · · · · · · · · · · · ·		

	FOREIGN PATENT DOCUMENTS							
	Cite		Foreign Patent Document		Name of Patentee or Applicant	Date of Publication of		
	No.	Office	Number	Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY		
	K	PCT	EP A1 0321 613		Bristol-Myers Company	06/28/1989		
	L	FR	2 768 339		De Neufville Axel	09/18/1997		

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.